Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial
06:02am, Tuesday, 18'th Nov 2025
The drugmaker said the results for giredestrant open the door to adding a treatment option at an early stage of the cancer, when most patients are diagnosed.
Roche oral drug shown to keep breast cancer at bay, boosting shares
05:06am, Tuesday, 18'th Nov 2025
Roche's ROG.S experimental oral drug giredestrant has been shown to cut the risk of recurrence of a common form of breast cancer after surgery, boosting the company's shares and underpinning its tradi
Genentech's Giredestrant Becomes the First Oral SERD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer
01:10am, Tuesday, 18'th Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive Phase III results from the lidERA Breast Cancer study evalua
Basel, 18 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive phase III results from the lidERA Breast Cancer study evaluating investigational giredestrant as an adjuvant endoc
Millennials at highest risk of missing crucial cervical cancer screenings, finds survey commissioned by Roche
01:00am, Wednesday, 12'th Nov 2025
New research shows that people aged 29-42 are more likely to miss cervical screenings than any other age group.1 Almost one third of surveyed European millennials eligible for routine cervical screeni
Why Roche Holding Stock Popped Today
01:39pm, Monday, 10'th Nov 2025
Roche reported positive Phase III results on trials of its new multiple sclerosis (MS) drug today. Fenebrutinib appears effective at treating both relapsing multiple sclerosis and primary progressive
TG Therapeutics Crumbles After Roche Unveils Its 'Unprecedented' Test Results
12:00pm, Monday, 10'th Nov 2025
Roche presented "unprecedented" test results for its multiple sclerosis treatment, putting pressure on key rival TG Therapeutics.
Roche Multiple Sclerosis Drug Meets Main Goals in Two Late-Stage Trials
02:03am, Monday, 10'th Nov 2025
Fenebrutinib met primary goals in two late-stage trials for the treatment of two different forms of multiple sclerosis.
Roche says MS drug candidate meets primary goal in late-stage trial
01:18am, Monday, 10'th Nov 2025
Roche said on Monday that a late-stage trial testing its multiple sclerosis drug candidate fenebrutinib against the relapsing form of the disease achieved its primary goal.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the first Phase III (FENhance 2) of two pivotal, similarly-desig
CellBxHealth jumps 10% after unveiling Roche-linked cancer testing study
03:43am, Wednesday, 05'th Nov 2025
Shares in CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY) rose 10% to 2.3p after the company revealed encouraging early results from a study showing its cancer cell detection platform works seamlessly with Ro
CellBxHealth teams up with Roche in cancer testing breakthrough
02:05am, Wednesday, 05'th Nov 2025
CelLBxHealth PLC (AIM:CLBX, NSX:ANPCY) has unveiled early results from a study that links its cancer cell detection technology with Roche's widely used diagnostic equipment, a step that could make b
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
09:00am, Monday, 03'rd Nov 2025
Basel, 3 November 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will showcase 46 abstracts, including 12 oral presentations, from its industry-leading haematology portfolio at the
BOSTON--(BUSINESS WIRE)--Manifold Bio, a platform therapeutics company pioneering AI-guided drug discovery coupled with direct-to-vivo measurement, today announced a strategic research collaboration a
Positive Phase III Data for Genentech's Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus
01:00am, Monday, 03'rd Nov 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from the
